Rapid Micro shares jump 10.86% intraday after reporting record $11.3M Q4 revenue and 37% year-over-year growth.

Rapid Micro Biosystems surged 10.86% intraday after reporting record preliminary unaudited results for Q4 2025, including $11.3 million in revenue (up 37% year-over-year) and 16 new Growth Direct system placements. Full-year 2025 revenue is projected at $33.6 million, a 20% increase, with recurring revenue rising 15% to $17.8 million. The company also validated three customer systems in Q4 and now has 190 systems placed globally, reflecting strong demand for its microbial quality control automation solutions. These results exceeded raised guidance and highlighted sustained growth in both new deployments and recurring revenue streams, bolstering investor confidence ahead of its J.P. Morgan Healthcare Conference presentation.